AHR antagonist 8 (compound SG-02) acts as a regulator of utrophin, a dystrophin analog, and serves as an AhR antagonist with a Kd of 41.68 nM. Studies demonstrate that 800 nM of AHR antagonist 8 can upregulate utrophin by 2.7 times. Additionally, AHR antagonist 8 enhances MyHC expression, indicating its potential to promote myogenesis. ADME evaluations reveal that AHR antagonist 8 possesses some oral bioavailability.